Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib study of S-222611 in patients with advanced EGFR- and/or HER2-expressing solid tumours

Trial Profile

Phase Ib study of S-222611 in patients with advanced EGFR- and/or HER2-expressing solid tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epertinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Gastrointestinal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Sep 2018 Results of the extended phase Ib study (n=76) published in the European Journal of Cancer
    • 12 Dec 2015 Results (n=76) presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 29 Oct 2015 Status changed from active, no longer recruiting to completed as results of both escalation and expansion phase are published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top